Inventor · disambiguated record
Kevin Flanigan
Also filed as: FLANIGAN KEVIN · FLANIGAN KEVIN M
3 granted patents·13 pending applications·11 citations·filing 2002–2023
66Inventor score
Files withRES INST NATIONWIDE CHILDRENS HOSPITAL12FLANIGAN KEVIN M1RES INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL1THE RES INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL1UNIV UTAH1
Top patents by PatentIndex Score
16 records- 0184US11230707B2Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructsRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2018·Granted Jan 25, 2022·3 cites·17 claims
- 0280US11053494B2Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD geneTHE RES INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL·Filed 2015·Granted Jul 6, 2021·2 cites·27 claims
- 0377US9862945B2Recombinant adeno-associated virus delivery of exon 2-targeted U7SNRNA polynucleotide constructsRES INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL·Filed 2014·Granted Jan 9, 2018·6 cites·14 claims
- 0467US2023025574A1Recombinant Adeno-Associated Virus Delivery of Exon 2-Targeted U7SNRNA Polynucleotide ConstructsRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2021·Application pending·0 cites
- 0560US2022127607A1Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd geneRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2021·Application pending·0 cites
- 0660US2025152740A1Materials and methods for the treatment of limb girdle muscular dystrophyRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2022·Application pending·0 cites
- 0757US2024209360A1Products and methods for inducing exon 2 skipping of the dmd gene in treating muscular dystrophyRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2022·Application pending·0 cites
- 0856US2024254509A1Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplicationsRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2022·Application pending·0 cites
- 0955US2024261434A1Products and methods for treating muscular dystrophyRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2021·Application pending·0 cites
- 1054US2023357795A1Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophyRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2021·Application pending·0 cites
- 1154US2024200066A1Products and methods for treating muscular dystrophyRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2022·Application pending·0 cites
- 1254US2024189453A1Materials and methods for neurofibromin 2/merlin (nf2) gene therapyRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2022·Application pending·0 cites
- 1352US2025186621A1Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefromRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2023·Application pending·0 cites
- 1451US2022282247A1Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathiesRES INST NATIONWIDE CHILDRENS HOSPITAL·Filed 2020·Application pending·0 cites
- 1546US2006223062A1Rapid direct sequence analysis of multi-exon genesFLANIGAN KEVIN M·Filed 2003·Application pending·0 cites
- 1644US2003049666A1Tissue culture assay for measuring drug induced translational recoding at premature stop codons and frameshift mutationsUNIV UTAH·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kevin Flanigan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →